E-viri
PDF
Recenzirano
Odprti dostop
-
Falsey, Ann R; Sobieszczyk, Magdalena E; Hirsch, Ian; Sproule, Stephanie; Robb, Merlin L; Corey, Lawrence; Neuzil, Kathleen M; Hahn, William; Hunt, Julie; Mulligan, Mark J; McEvoy, Charlene; DeJesus, Edwin; Hassman, Michael; Little, Susan J; Pahud, Barbara A; Durbin, Anna; Pickrell, Paul; Daar, Eric S; Bush, Larry; Solis, Joel; Carr, Quito Osuna; Oyedele, Temitope; Buchbinder, Susan; Cowden, Jessica; Vargas, Sergio L; Guerreros Benavides, Alfredo; Call, Robert; Keefer, Michael C; Kirkpatrick, Beth D; Pullman, John; Tong, Tina; Brewinski Isaacs, Margaret; Benkeser, David; Janes, Holly E; Nason, Martha C; Green, Justin A; Kelly, Elizabeth J; Maaske, Jill; Mueller, Nancy; Shoemaker, Kathryn; Takas, Therese; Marshall, Richard P; Pangalos, Menelas N; Villafana, Tonya; Gonzalez-Lopez, Antonio
The New England journal of medicine, 12/2021, Letnik: 385, Številka: 25Journal Article
In a randomized, double-blind, placebo-controlled phase 3 trial of the ChAdOx1 nCoV-19 vaccine in over 32,000 participants from the United States, Chile, and Peru, the incidence of serious adverse effects was low (including no cases of vaccine-induced immune thrombotic thrombocytopenia) and the vaccine efficacy was 74%. Efficacy was documented in a range of demographic subgroups.
